Altered microRNA expression during Impaired Glucose Tolerance and High-fat Diet Feeding

Abstract

Objective MicroRNAs (miRNAs) play a critical role in metabolic regulation. Recently, we identified novel miRNAs in the whole blood of South African women of mixed ethnic ancestry. The aim of this study was to investigate whether five of these novel miRNAs are expressed in serum and whether their expression is altered during metabolic dysregulation.

Methods Expression levels of the five novel miRNAs (MYN08, MYNO22, MYN059, MYNO66 and MYNO95) were measured in the serum of women with Impaired Glucose Tolerance (IGT) and Normoglycemia (NGT) (n=24), and in the whole blood of vervet monkeys fed a high-fat or standard diet (n=16) using quantitative real-time PCR.

Results Only three of the selected novel miRNAs (MYNO8, MYNO22 and MYNO66) were expressed in serum. The expression of MYN08 and MYNO22 were associated with fasting glucose and insulin concentrations, decreased during IGT and able to predict IGT. The expression of these miRNAs were similarly decreased in vervet monkeys fed a high-fat diet. In silico analysis identified a total of 291 putative messenger RNA targets for MYNO8 and MYNO22, including genes involved in gluconeogenesis, carbohydrate metabolism, glucose homeostasis and lipid transport.

Conclusion Two novel miRNAs, MYNO8 and MYNO22, are associated with metabolic dysregulation in South African women of mixed ethnic ancestry and with high-fat diet feeding in vervet monkeys. Furthermore, putative gene targets were enriched in biological processes involved in key aspects of glucose regulation, which strengthens the candidacy of these miRNAs as biomarkers for dysglycemia, and warranting further studies to assess their clinical applicability.

Key words

novel - microRNAs - quantitative real-time PCR - impaired glucose tolerance - vervet monkeys - high-fat diet

• References

• 1 Guariguata L, Whiting DR, Hambleton I. et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014; 103: 137-149
• 2 Tripathy D, Chavez AO. Defects in insulin secretion and action in the pathogenesis of type 2 diabetes mellitus. Curr Diab Rep 2010; 10: 184-191
• 3 Nathan DM, Davidson MB, DeFronzo RA. et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30: 753-759
• 4 Knowler WC, Barrett-Connor E, Fowler SE. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
• 5 Friedman RC, Farh KK-H, Burge CB. et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105
• 6 Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20
• 7 Guo H, Ingolia NT, Weissman JS. et al. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-840
• 8 Guay C, Roggli E, Nesca V. et al. Diabetes mellitus, a microRNA-related disease?. Transl Res J Lab Clin Med 2011; 157: 253-264
• 9 Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?. Circ Res 2012; 110: 483-495
• 10 Guay C, Regazzi R. Exosomes as new players in metabolic organ cross-talk. Diabetes Obes Metab 2017; 19 (Suppl. 01) 137-146
• 11 Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci 2012; 37: 460-465
• 12 Guay C, Regazzi R. New emerging tasks for microRNAs in the control of β-cell activities. Biochim Biophys Acta 2016; 1861: 2121-2129
• 13 Dias S, Hemmings S, Muller C et al. MicroRNA Expression Varies according to Glucose Tolerance, Measurement Platform, and Biological Source. BioMed Research International 2017; 1080157:1–10
• 14 de Wit E, Delport W, Rugamika CE. et al. Genome-wide analysis of the structure of the South African Coloured Population in the Western Cape. Hum Genet 2010; 128: 145-153
• 15 Erasmus RT, Soita DJ, Hassan MS. et al. High prevalence of diabetes mellitus and metabolic syndrome in a South African coloured population: baseline data of a study in Bellville, Cape Town. South Afr Med J Suid-Afr Tydskr Vir Geneeskd 2012; 102: 841-844
• 16 World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. 2006; 1–50. Geneva: World Health Organization
• 17 Pheiffer C, Dias S, Muller C. et al. Decreased global DNA methylation in the white blood cells of high fat diet fed vervet monkeys (Chlorocebus aethiops). J Physiol Biochem 2014; 70: 725-733
• 18 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods San Diego Calif 2001; 25: 402-408
• 19 Agarwal V, Bell GW, Nam J-W et al. Predicting effective microRNA target sites in mammalian mRNAs. eLife 2015; 4:
• 20 Betel D, Koppal A, Agius P. et al. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol 2010; 11: R90
• 21 Gene Ontology Consortium. Blake JA, Dolan M, Drabkin H et al. Gene Ontology annotations and resources. Nucleic Acids Res 2013; 41: D530–D535
• 22 Mi H, Thomas P. PANTHER pathway: an ontology-based pathway database coupled with data analysis tools. Methods Mol Biol Clifton NJ 2009; 563: 123-140
• 23 Párrizas M, Brugnara L, Esteban Y. et al. Circulating miR-192 and miR-193b are markers of prediabetes and are modulated by an exercise intervention. J Clin Endocrinol Metab 2015; 100: E407-E415
• 24 Yang Z, Chen H, Si H. et al. Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes. Acta Diabetol 2014; 51: 823-831
• 25 Luo M, Li R, Deng X. et al. Platelet-derived miR-103b as a novel biomarker for the early diagnosis of type 2 diabetes. Acta Diabetol 2015; 52: 943-949
• 26 Zampetaki A, Kiechl S, Drozdov I. et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107: 810-817
• 27 Karolina DS, Armugam A, Tavintharan S. et al. MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PloS One 2011; 6: e22839
• 28 Mayeux R. Biomarkers: Potential Uses and Limitations. NeuroRx 2004; 1: 182-188
• 29 Louw J, Woodroof C, Seier J. et al. The effect of diet on the Vervet monkey endocrine pancreas. J Med Primatol 1997; 26: 307-311
• 30 Fincham JE, Faber M, Weight MJ. et al. Diets realistic for westernized people significantly effect lipoproteins, calcium, zinc, vitamins C, E, B6 and haematology in vervet monkeys. Atherosclerosis 1987; 66: 191-203
• 31 Qiu C, Chen G, Cui Q. Towards the understanding of microRNA and environmental factor interactions and their relationships to human diseases. Sci Rep 2012; 2: 318
• 32 Vigneron N, Meryet-Figuière M, Guttin A. et al. Towards a new standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous normalization to improve miRNA signature accuracy. Mol Oncol 2016; 10: 981-992